drugset / Trial / NCT00426283

A Study of Flovent in Patients With Eosinophilic Esophagitis

NCT00426283

Phase 2 Completed 42 enrolled Marc Rothenberg, MD
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to test the effects (both good and bad) of high dose swallowed fluticasone propionate (Flovent) in subjects with eosinophilic esophagitis (EoE).

Timeline

Start
2007-01
Primary completion
2011-12
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 1760 ug Oral